ADIL (Adial Pharmaceuticals Inc) stock: $4.86, $12.8M market cap, $28.7M cash, -$15.9M EV, $26.8M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Share price
$4.86
Market cap
$12.8M
Cash
$28.7M
Enterprise value
-$15.9M
Balance sheet
Cash
$28.7M
Debt
$0.0M
Net cash
$28.7M
Enterprise value
-$15.9M
Basic shares
2.6M shares
Fully diluted shares
5.5M shares
Fully diluted market cap
$26.8M
Cash per share
$11.04
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading ADIL daily closes…
Loading price history…
Pipeline assets
AT177
Preclinical · ActiveModality: oral, colon-targeted, fully-synthetic small molecule
Target AhR (aryl hydrocarbon receptor)
Indications
Ulcerative colitis(Stage not disclosed)
Status note Lead program after June 11, 2026 merger with Azora Therapeutics. Milestone warrant terms reference first patient dosed in a Phase 1 trial of AT177 (or IND acceptance), indicating IND not yet accepted in this filing.
Partnerships Molteni Farmaceutici: framework agreement for a proposed exclusive partnership covering AD04 commercialization in Europe (definitive agreement not yet executed)
Indications
Alcohol use disorder (AUD) in biomarker-positive genotypes(Phase 3)
Status note ONWARD Phase 3 trial investigated AD04 in AUD patients with HTR3A/HTR3B genotypes identified via companion diagnostic; company now focused on completing the development program in specified subpopulations. No dated forward catalysts in the filing. AD04 is low-dose ondansetron (~1/100th of the withdrawn 32 mg i.v. Zofran dose).
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.